# p53

p53 is a Private Equity based in Stavanger, Norway.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Stavanger, Norway
- **Region:** Europe
- **Address:** Stavanger, Norway
- **Founded:** 2018
- **Assets under management:** Undisclosed
- **Website:** p53.no
- **LinkedIn:** https://www.linkedin.com/company/p53

## Regulatory record

- **Reports private funds:** No

## About

p53 is a Norwegian healthcare investment company dedicated to investing in the healthcare sector. They identify and invest in healthcare companies that think new and disrupt the status quo. The firm believes in long-term value creation and aims to be an active owner in core investments, contributing knowledge, experience, and network alongside long-term capital.

## Sectors

- Healthcare Services
- Biotechnology

## People

- Susanne Stuffers — Co-founder
- Øyvind Schanke — Chief Investment Officer, TD Veen
- Silje Veen — Chair of the Board, TD Veen
- Kjell Skappel — CEO, TD Veen
- Lars — Team member

## Questions

### Who runs investment decisions at p53?

Investment decisions rest with co-founder Susanne Stuffers, supported by TD Veen's CIO Øyvind Schanke. Stuffers, an M.D. and Ph.D. with clinical oncology experience and sell-side equity research background, leads scientific and commercial due diligence. TD Veen's CEO Kjell Skappel and chair Silje Veen govern the overall capital allocation.

### How does p53 source proprietary deal flow?

Proprietary sourcing draws on the team's deep Scandinavian academic and clinical networks, particularly through Oslo's Radiumhospital, where multiple team members studied or researched. Deal flow also comes from relationships with European life-science VCs like Forbion and Sunstone, and from management teams' direct outreach to a concentrated capital source.

### What investment stages does p53 typically target?

p53 invests across preclinical and clinical stages. The portfolio includes preclinical platform companies like Valink Therapeutics, clinical-stage biotechs like Calluna Pharma, and later-stage public companies such as Nykode Therapeutics, reflecting a flexible mandate across the development timeline.

### Which sectors does p53 explicitly avoid?

p53 is exclusively focused on healthcare and life sciences. It does not invest in software, consumer, industrials, or any sector outside biotechnology, pharmaceuticals, and healthcare innovation, in line with its mandate as TD Veen's sole healthcare-dedicated vehicle.

### How is p53 related to TD Veen?

p53 was founded in 2018 as a subsidiary of TD Veen, the Stavanger-based family investment company. All p53 investments align with TD Veen's strategy and objectives. TD Veen's senior leadership — Kjell Skappel, Silje Veen, and Øyvind Schanke — are integral to p53's governance and investment processes.

### Does p53 participate in fund commitments or only direct deals?

p53 executes direct equity investments in private and public healthcare companies. It does not disclose commitments to third-party funds. Its model centers on active, direct ownership with board engagement, often alongside co-investors it selects for strategic alignment.

## Related profiles

- [P4G Capital Management](https://altss.com/profile/p4g-capital-management)
- [P5 Health Ventures](https://altss.com/profile/p5-health-ventures)

---

Last updated: 2026-08-11T15:07:41.444Z

Canonical page: https://altss.com/profile/p53

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology